Insider Cluster ·Filed Mar 25, 2026

NUVL

Nuvalent, Inc.
BEARISH
Impact 6/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $1.5M total
Actionable Insight ▼ Bearish

While the total dollar amount is not highly material relative to market cap, the concentration of selling by top executives — especially the CFO — raises caution. Traders should monitor for further selling, upcoming earnings, or potential negative catalysts. Non-cash derivative exercises should not be interpreted as economic transactions.

DirectionBearish
Confidencelow
Horizondays
Final — all horizons settled through T+60d
NUVL ▲ +25.94% at T+60d
SHORT call ✗ call lost -25.94% · α vs SPY -12.49% · entry $98.00 → $123.43
Entry anchored
Mar 24, 03:59 PM ET
via exchange tick
T+1d
+0.06%
call -0.06% · α -1.83%
$98.06
settled 6mo ago
T+5d
+7.80%
call -7.80% · α -8.04%
$105.64
settled 6mo ago
T+20d
+2.54%
call -2.54% · α +5.32%
$100.49
settled 5mo ago
T+60d
+25.94%
call -25.94% · α -12.49%
$123.43
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Analysis based on filing metadata only — document content was unavailable. Cross-filing context reveals a recent insider trading cluster involving open-market sales by Nuvalent's CFO and Chief Legal Officer, with total reported sales exceeding $1.7 million over the past week.

Key Financial Metrics

Direction
selling

Key Facts

  • Insider trading cluster reported for Nuvalent, Inc. (NUVL) with transactions over a 7-day window
  • CFO Alexandra Balcom sold over $1.6 million in shares, including a $1.37M open-market sale on March 25
  • Chief Legal Officer Deborah Miller sold $91,650 in shares on March 26
  • Multiple derivative exercises occurred, but these are non-cash events with no direct market impact
  • Total open-market sales by insiders exceed $1.7 million in the past week

Financial Impact

$1.71M in open-market sales by corporate insiders over 7 days, representing approximately 0.02% of Nuvalent's $7.6B market cap

insider ownershipinvestor sentiment

Risk Factors

  • Perception of insider pessimism due to CFO and CLO selling
  • Potential for negative sentiment despite modest dollar volume

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

Report based on filing metadata.

18 reports for NUVL
Performance horizon
43% Hit rate 3 of 7 directional calls best @ T+60▲ +21.01%Apr 7, 2026
Filters
Rows
Reports for NUVL — sortable, filterable
TypeNow
Jul 27, 2026
9w ago
15-12G
NEUTRAL ★ 3/10
—awaiting T+5——
Jul 15, 2026
11w ago
25-NSE
NEUTRAL ★ 3/10
$123.96 $123.96· 0.00%▲ +0.98%—
Jul 15, 2026
11w ago
8-K
BULLISH ★ 5/10
$123.96 $123.96· 0.00%▲ +0.98%—
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.80 $123.96▲ +0.13%▼ −0.73%—
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.72 $123.90▲ +0.15%▼ −0.34%—
Jun 11, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$123.25 $123.43▲ +0.15%▼ −0.53%—
Jun 10, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.45 $123.36▼ −0.07%▼ −0.51%—
Jun 9, 2026
16w ago
8-K
BULLISH ★ 8/10
$123.25 $123.35▲ +0.08%▼ −2.33%—
May 7, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$102.40 $105.22▲ +2.75%▲ +1.25%—
Apr 29, 2026
22w ago
Insider Cluster
NEUTRAL ★ 2/10
$99.10 $101.47▲ +2.39%▼ −0.72%—
Showing 10 of 18

US Market Status

Market Open — Closes in 3h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 30, 2026